Becton, Dickinson and Company (NYSE:BDX) Shares Unloaded Rep. Jefferson Shreve

Representative Jefferson Shreve (R-Indiana) recently sold shares of Becton, Dickinson and Company NYSE: BDX. In a filing disclosed on April 11th, the Representative disclosed that they had sold between $15,001 and $50,000 in Becton, Dickinson and Company stock on March 5th. The trade occurred in the Representative's "CRT - STANDARD UNIT TRUST" account.

Representative Jefferson Shreve also recently made the following trade(s):

• Purchased $15,001 - $50,000 in shares of Harley-Davidson NYSE: HOG on 3/31/2025.
• Purchased $50,001 - $100,000 in shares of Block NYSE: XYZ on 3/31/2025.
• Sold $15,001 - $50,000 in shares of DuPont de Nemours NYSE: DD on 3/31/2025.
• Purchased $15,001 - $50,000 in shares of United Community Banks NASDAQ: UCB on 3/31/2025.
• Sold $15,001 - $50,000 in shares of IDEX NYSE: IEX on 3/31/2025.
• Purchased $15,001 - $50,000 in shares of HNI NYSE: HNI on 3/31/2025.
• Sold $50,001 - $100,000 in shares of ServiceNow NYSE: NOW on 3/31/2025.
• Sold $15,001 - $50,000 in shares of Coinbase Global NASDAQ: COIN on 3/31/2025.
• Sold $15,001 - $50,000 in shares of Constellation Energy NASDAQ: CEG on 3/31/2025.
• Sold $50,001 - $100,000 in shares of Simon Property Group NYSE: SPG on 3/31/2025.

Becton, Dickinson and Company Stock Performance

Becton, Dickinson and Company stock traded down $1.91 during midday trading on Friday, hitting $198.50. 4,062,543 shares of the company's stock were exchanged, compared to its average volume of 1,710,218. The stock has a market cap of $56.99 billion, a price-to-earnings ratio of 32.97, a price-to-earnings-growth ratio of 1.63 and a beta of 0.35. Becton, Dickinson and Company has a 12-month low of $193.03 and a 12-month high of $251.99. The firm's 50 day simple moving average is $220.84 and its 200 day simple moving average is $228.58. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.63 and a current ratio of 1.13.

Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last announced its quarterly earnings data on Wednesday, February 5th. The medical instruments supplier reported $3.43 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.00 by $0.43. Becton, Dickinson and Company had a net margin of 8.47% and a return on equity of 15.74%. Equities research analysts predict that Becton, Dickinson and Company will post 14.43 EPS for the current year.

Becton, Dickinson and Company declared that its Board of Directors has initiated a share repurchase program on Tuesday, January 28th that allows the company to buyback 10,000,000 outstanding shares. This buyback authorization allows the medical instruments supplier to purchase shares of its stock through open market purchases. Stock buyback programs are usually an indication that the company's management believes its stock is undervalued.

Becton, Dickinson and Company Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Monday, March 31st. Investors of record on Monday, March 10th were paid a dividend of $1.04 per share. The ex-dividend date of this dividend was Monday, March 10th. This represents a $4.16 annualized dividend and a yield of 2.10%. Becton, Dickinson and Company's dividend payout ratio is currently 69.10%.

Insider Buying and Selling

In other news, EVP Richard Byrd sold 1,940 shares of the business's stock in a transaction that occurred on Wednesday, March 12th. The stock was sold at an average price of $224.91, for a total value of $436,325.40. Following the completion of the sale, the executive vice president now directly owns 7,411 shares in the company, valued at approximately $1,666,808.01. The trade was a 20.75 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Michael David Garrison sold 479 shares of the firm's stock in a transaction dated Wednesday, April 9th. The stock was sold at an average price of $197.28, for a total transaction of $94,497.12. Following the completion of the transaction, the executive vice president now owns 4,887 shares in the company, valued at approximately $964,107.36. The trade was a 8.93 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 4,078 shares of company stock valued at $915,986. Corporate insiders own 0.36% of the company's stock.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in BDX. Vanguard Group Inc. raised its holdings in shares of Becton, Dickinson and Company by 0.7% in the 4th quarter. Vanguard Group Inc. now owns 26,743,052 shares of the medical instruments supplier's stock worth $6,067,196,000 after purchasing an additional 184,288 shares during the period. T. Rowe Price Investment Management Inc. increased its position in shares of Becton, Dickinson and Company by 36.1% in the fourth quarter. T. Rowe Price Investment Management Inc. now owns 12,126,707 shares of the medical instruments supplier's stock worth $2,751,187,000 after acquiring an additional 3,219,317 shares in the last quarter. Geode Capital Management LLC boosted its position in Becton, Dickinson and Company by 1.1% during the 4th quarter. Geode Capital Management LLC now owns 6,351,537 shares of the medical instruments supplier's stock worth $1,437,161,000 after purchasing an additional 66,024 shares during the period. Massachusetts Financial Services Co. MA boosted its position in shares of Becton, Dickinson and Company by 15.1% in the fourth quarter. Massachusetts Financial Services Co. MA now owns 6,175,899 shares of the medical instruments supplier's stock worth $1,401,126,000 after buying an additional 810,345 shares during the period. Finally, First Eagle Investment Management LLC raised its holdings in shares of Becton, Dickinson and Company by 31.4% during the 4th quarter. First Eagle Investment Management LLC now owns 4,426,022 shares of the medical instruments supplier's stock valued at $1,004,132,000 after buying an additional 1,057,879 shares during the period. 86.97% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

BDX has been the subject of several recent analyst reports. Piper Sandler raised their price target on Becton, Dickinson and Company from $275.00 to $280.00 and gave the company an "overweight" rating in a report on Tuesday, January 28th. Barclays dropped their target price on shares of Becton, Dickinson and Company from $279.00 to $261.00 and set an "overweight" rating for the company in a report on Monday, April 7th. Finally, StockNews.com upgraded Becton, Dickinson and Company from a "hold" rating to a "buy" rating in a research report on Wednesday, April 2nd. Eight analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock has an average rating of "Buy" and an average price target of $275.71.

About Representative Shreve

Jefferson Shreve (Republican Party) is a member of the U.S. House, representing Indiana's 6th Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027. Shreve (Republican Party) is running for re-election to the U.S. House to represent Indiana's 6th Congressional District. He declared candidacy for the 2026 election. Email editor@ballotpedia.org to notify us of updates to this biography. Jefferson Shreve earned a bachelor's degree from Indiana University in 1989, a graduate degree from the University of London in 1998, and a graduate degree from Purdue University in 2003. Shreve's career experience includes working as a real estate executive. Shreve was elected 7th District Vice Chairman of the Indiana Republican State Committee on January 17, 2018, and was re-elected on March 6, 2021. In 2020, he was selected as a district-level delegate to the 2020 Republican National Convention.

About Becton, Dickinson and Company

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.